SPI1
Transcription factor PU.1
Also known as: OF, PU.1, SFPI1, SPI-1, SPI-A, SPI1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P17947
- Gene
- SPI1
- Ensembl
- ENSG00000066336
- Chromosome
- 11
- Canonical length
- 270 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
This gene encodes an ETS-domain transcription factor that activates gene expression during myeloid and B-lymphoid cell development. The nuclear protein binds to a purine-rich sequence known as the PU-box found near the promoters of target genes, and regulates their expression in coordination with other transcription factors and cofactors. The protein can also regulate alternative splicing of target genes. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
270 residues, UniProt reviewed canonical sequence.
>P17947|SPI1
1 MLQACKMEGF PLVPPPSEDL VPYDTDLYQR QTHEYYPYLS SDGESHSDHY WDFHPHHVHS
61 EFESFAENNF TELQSVQPPQ LQQLYRHMEL EQMHVLDTPM VPPHPSLGHQ VSYLPRMCLQ
121 YPSLSPAQPS SDEEEGERQS PPLEVSDGEA DGLEPGPGLL PGETGSKKKI RLYQFLLDLL
181 RSGDMKDSIW WVDKDKGTFQ FSSKHKEALA HRWGIQKGNR KKMTYQKMAR ALRNYGKTGE
241 VKKVKKKLTY QFSGEVLGRG GLAERRHPPHLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SPI1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.6
- Highest tissue expression
- 316 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 316 nTPM
- spleen: 168 nTPM
- appendix: 101 nTPM
- lung: 99 nTPM
- lymph node: 61 nTPM
- adipose tissue: 35 nTPM
Single-cell type
- neutrophils: 1,364 nCPM
- hofbauer cells: 502 nCPM
- kupffer cells: 450 nCPM
- monocytes: 449 nCPM
- cdc: 417 nCPM
- neutrophil progenitors: 394 nCPM
Immune cell
- eosinophil: 180 nTPM
- neutrophil: 84 nTPM
- non-classical monocyte: 35 nTPM
- intermediate monocyte: 28 nTPM
- classical monocyte: 19 nTPM
- myeloid DC: 16 nTPM
Brain region
- medulla oblongata: 69 nTPM
- white matter: 67 nTPM
- thalamus: 59 nTPM
- pons: 56 nTPM
- spinal cord: 45 nTPM
- cerebral cortex: 41 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SPI1.
Disease | AllUniProt
Conditions SPI1 is implicated in, by any mechanism.
- Agammaglobulinemia 10, autosomal dominant (AGM10) MIM:619707
Disease | GeneticClinVar
25 pathogenic / likely-pathogenic of 177 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Agammaglobulinemia
- Agammaglobulinemia 10, autosomal dominant
- PU.1-mutated agammaglobulinemia
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.24
- gnomAD pLI
- 0.98
- gnomAD missense Z
- 2.35
- DepMap mean gene effect
- -0.06
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- anatomical structure regression
- apoptotic process involved in blood vessel morphogenesis
- cell differentiation
- cellular response to ethanol
- defense response to tumor cell
- endothelial to hematopoietic transition
- erythrocyte differentiation
- follicular B cell differentiation
- germinal center B cell differentiation
- granulocyte differentiation
- immature B cell differentiation
- interleukin-6-mediated signaling pathway
- lipopolysaccharide-mediated signaling pathway
- macrophage differentiation
- myeloid dendritic cell differentiation
- myeloid leukocyte differentiation
- negative regulation of adipose tissue development
- negative regulation of canonical NF-kappaB signal transduction
- negative regulation of DNA-templated transcription
- negative regulation of gene expression
- negative regulation of MHC class II biosynthetic process
- negative regulation of neutrophil degranulation
- negative regulation of non-canonical NF-kappaB signal transduction
- negative regulation of protein localization to chromatin
- negative regulation of transcription by RNA polymerase II
- oncogene-induced cell senescence
- osteoclast differentiation
- pericyte cell differentiation
- positive regulation of antifungal innate immune response
- positive regulation of B cell differentiation
- positive regulation of microglial cell mediated cytotoxicity
- positive regulation of miRNA transcription
- positive regulation of myeloid dendritic cell chemotaxis
- positive regulation of p38MAPK cascade
- positive regulation of transcription by RNA polymerase II
- pro-T cell differentiation
- regulation of DNA-templated transcription
- regulation of erythrocyte differentiation
- regulation of myeloid progenitor cell differentiation
- regulation of transcription by RNA polymerase II
- somatic stem cell population maintenance
- TRAIL-activated apoptotic signaling pathway
- transcription initiation-coupled chromatin remodeling
- transforming growth factor beta receptor signaling pathway
Molecular functions
- chromatin binding
- cis-regulatory region sequence-specific DNA binding
- DNA-binding transcription activator activity
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity
- DNA-binding transcription factor activity, RNA polymerase II-specific
- DNA-binding transcription factor binding
- DNA-binding transcription repressor activity
- DNA-binding transcription repressor activity, RNA polymerase II-specific
- histone deacetylase binding
- NFAT protein binding
- protein sequestering activity
- RNA binding
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- RNA polymerase II-specific DNA-binding transcription factor binding
- sequence-specific DNA binding
- STAT family protein binding
- transcription cis-regulatory region binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SPI1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SPI1 as an antibody target. Whether an autoantibody or antibody against SPI1 could matter depends on whether native SPI1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SPI1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SPI1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...